ArticleFrontiers in microbiology2020
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- In Vivo Evaluation of a Nanoemulsion-Delivered Chromium(III)-Triazole Complex Against Fluconazole-ResistantJournal of fungi (Basel, Switzerland) · 2026Article
- Article
- In Vitro Assessment of the Combined Activity of Amphotericin B and CuTropical medicine and infectious disease · 2025Article
- Biological Activity of Silver(I)-1,10-Phenanthroline Complexes AgainstPharmaceuticals (Basel, Switzerland) · 2025Article
- Toxicity Assessment and Antifungal Potential of Copper(II) and Silver(I) Complexes with 1,10-Phenanthroline-5,6-dione Against Drug-Resistant Clinical Isolates ofJournal of fungi (Basel, Switzerland) · 2025Article
- Apoptotic cell death induced by copper (II), manganese (II) and silver (I) complexes containing bridging dicarboxylate and 1,10-phenanthroline ligands: one of the multi-modes of anticancer activity?Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025Article
- Anthelmintic activity of 1,10-phenanthroline-5,6-dione-based metallodrugs.Scientific reports · 2025Article
- Exploring the Epicarp Potential fromAntioxidants (Basel, Switzerland) · 2025Article
- Combating EnteroaggregativeAIMS microbiology · 2025Article
- Impact of Copper(II) and Silver(I) Complexes Containing 1,10-phenanthroline-5,6-dione on Cellular and Virulence Aspects ofCurrent topics in medicinal chemistry · 2025Article
- Unveiling the antifungal mechanisms of CTP, a new copper(II)-theophylline/1,10-phenanthroline complex, on drug-resistant non-albicans Candida species.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Article
- Antifungal potential of the new copper(II)-theophylline/1,10-phenanthroline complex against drug-resistant Candida species.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Article
- Synthesis, characterisation, and solution behaviour of Ag(I) bis(phenanthroline-oxazine) complexes and the evaluation of their biological activity against the pathogenic yeast Candida albicans.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023Article
- Article
- The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs.International journal of molecular sciences · 2023Review
- Review
- Silver(I) 1,10-Phenanthroline Complexes Are Active againstJournal of fungi (Basel, Switzerland) · 2023Article
- Review
- Article
- In Vivo Activity of Metal Complexes Containing 1,10-Phenanthroline and 3,6,9-Trioxaundecanedioate Ligands againstBiomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.